Headlines about Compugen (NASDAQ:CGEN) have been trending somewhat negative this week, Accern reports. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Compugen earned a coverage optimism score of 0.00 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 45.7070519134226 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Compugen (NASDAQ:CGEN) traded down $0.15 during mid-day trading on Monday, reaching $2.55. The company’s stock had a trading volume of 301,382 shares, compared to its average volume of 225,070. Compugen has a 1-year low of $2.25 and a 1-year high of $5.40. The company has a market cap of $138.06, a P/E ratio of -3.59 and a beta of 0.68.
Compugen (NASDAQ:CGEN) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.19) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.19). sell-side analysts expect that Compugen will post -0.73 EPS for the current fiscal year.
CGEN has been the subject of several recent analyst reports. Zacks Investment Research downgraded Compugen from a “hold” rating to a “sell” rating in a research note on Wednesday, November 29th. ValuEngine downgraded Compugen from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st.
WARNING: “Compugen (NASDAQ:CGEN) Earning Somewhat Critical News Coverage, Analysis Finds” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/05/somewhat-critical-news-coverage-somewhat-unlikely-to-affect-compugen-cgen-share-price.html.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.